Rhythmic Sensory Stimulation on Fibromyalgia
An Investigation of the Effects of Rhythmic Sensory Stimulation on Fibromyalgia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients with clinical diagnosis of fibromyalgia
- able to read and write English adequately
- have satisfactory hearing bilaterally (self-reported)
- have the ability to operate the supplied device
Exclusion Criteria:
- acute and active inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis, autoimmune disease)
- medical or psychiatric illness
- history of psychosis, epilepsy, seizures
- pregnancy or breast feeding
- hemorrhaging or active bleeding
- thrombosis, angina pectoris
- heart disease, such as hypotension, arrhythmia, pacemaker
- substance abuse (harmful or hazardous use of psychoactive subtances, including alcohol and illicit drugs) in the last year
- suffering from a recently prolapsed vertebral disc
- recovering from a recent accident with back or neck injury.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: control
healthy controls n = 10 |
|
|
Active Comparator: patients
patients with fibromyalgia n =20 |
Participants will undertake 15 self-administered sessions of RSS 40Hz low frequency sound stimulation, 30 minutes daily, over 3 weeks (5 days/week).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in inflammatory cytokine levels
Time Frame: baseline, 1 month, 2 months
|
The investigator will use a multiplex enzyme-linked immunosorbent assay (ELISA) to asses inflammatory cytokines in fibromyalgia.
|
baseline, 1 month, 2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in pain severity
Time Frame: baseline, 1 month, 2 months
|
Patients will rate their pain severity on a scale from 0 (no pain) to 10 (extreme pain)
|
baseline, 1 month, 2 months
|
|
change in EEG brain activity
Time Frame: baseline, 1 month, 2 months
|
The investigators will measure EEG dynamics to quantify dysfunctional activity in brain areas that are affected by fibromyalgia
|
baseline, 1 month, 2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FibroMusicTherapy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.